BiotechTube

MK-0524A + Atorvastatin + Simvastatin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mixed Hyperlipidemia

Conditions

Mixed Hyperlipidemia

Trial Timeline

Jan 24, 2006 → Aug 6, 2010

NCT ID
NCT00289900

About MK-0524A + Atorvastatin + Simvastatin

MK-0524A + Atorvastatin + Simvastatin is a phase 3 stage product being developed by Merck for Mixed Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00289900. Target conditions include Mixed Hyperlipidemia.

What happened to similar drugs?

2 of 16 similar drugs in Mixed Hyperlipidemia were approved

Approved (2) Terminated (2) Active (12)
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
🔄olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
🔄Lurasidone + PlaceboSumitomo PharmaPhase 3
🔄Inclisiran + Matching Placebo for InclisiranNovartisPhase 3
✅TegaserodNovartisApproved
🔄FluvastatinNovartisPhase 3
🔄Atorvastatin + EvolocumabAmgenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00289900Phase 3Completed

Competing Products

20 competing products in Mixed Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
Lurasidone + PlaceboSumitomo PharmaPhase 3
40
Inclisiran + Matching Placebo for InclisiranNovartisPhase 3
40
TegaserodNovartisApproved
43
FluvastatinNovartisPhase 3
40
Atorvastatin + EvolocumabAmgenPhase 3
40
Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to AtorvastatinAmgenPhase 3
40
Blinatumomab in combination with donor lymphocyte infusionAmgenPhase 2
27
Evolocumab + AtorvastatinAmgenPhase 3
40
Evolocumab + Standard of CareAmgenPhase 3
40
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
32
Bococizumab + PlaceboPfizerPhase 3
32
tafamidisPfizerPre-clinical
26
IBI306 + placebo + placebo + IBI306Innovent BiologicsPhase 3
47
KarXTBristol Myers SquibbPhase 3
47
KarXTBristol Myers SquibbPhase 3
47
Gemcitabine + OxaliplatinSanofiPhase 2
35
XL765 (SAR245409) + TemozolomideSanofiPhase 1
29
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40